Twenty-three patients from cohorts 1 and 2 received targeted treatments based on their genomic profiles (20 with EGFR-sensitizing mutations, 1 with EGFR secondary mutation T790M and 2 with ERBB2 exon20 insertions), among which, 10 were treated based on the mutations detected by PE-cfDNA testing due to their tumor tissues being inaccessible (Figure 2C, marked by “*”). This evidence concerns the gene EGFR and neoplasm.